SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing significant upward momentum, challenging key resistance levels and fueling community discussion around potential short squeezes. A major talking point centers on geopolitical factors, with many speculating that international entities are increasing their Bitcoin holdings to bypass sanctions and hedge against devaluing national currencies. This perceived safe-haven demand is contributing to strong spot interest and a notable divergence from broader market weakness.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is capturing significant attention following a notable price rally, driven by increasing institutional staking activity and fresh optimism surrounding potential spot ETF approvals. The community is buzzing with short squeeze narratives and growing confidence in Ethereum's pivotal role in DeFi, stablecoins, and the broader tokenization of real-world assets, anticipating further upside.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies Inc. ($BMNR) is a major focus for investors due to an impending shareholder vote on a significant increase in authorized shares and executive compensation, generating intense debate. Many retail investors voice strong concerns about potential massive dilution and the stock's notable underperformance relative to Ethereum's price movements, leading to widespread criticism of management. The community is actively discussing whether this vote will enable future growth through its Ethereum staking strategy or further erode shareholder value.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is generating buzz due to ongoing discussions around the anticipated Digital Asset Market Clarity Act markup and reports of Ripple's stablecoin, RLUSD, being utilized by major financial institutions like BlackRock. While many in the community anticipate significant gains from increased institutional adoption and regulatory clarity, there's notable frustration over XRP's price lagging behind Bitcoin, sparking ongoing debates about market manipulation and its potential for independent movement.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending amidst strong speculative interest, fueled by discussions of positive technical indicators and reports highlighting its outperformance against Bitcoin and Ethereum. The community maintains a fervent 'buy the dip' mentality, anticipating a significant price rally driven by its meme coin status and broader crypto market movements.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is actively trending after its recent substantial Bitcoin acquisition, intensifying the ongoing debate around its unique corporate strategy. Bulls are rallying, anticipating a significant short squeeze and higher valuations, while a skeptical segment of the community questions the long-term impact of continuous share issuance to fund these large crypto purchases.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending as strong preliminary Q4 2025 results and an optimistic 2026 revenue outlook, including a potential path to $1 billion in Briumvi global sales, drive conversation following its JPM Healthcare Conference presentation. Investors are largely bullish on Briumvi's best-in-class profile and competitive advantages, especially after setbacks for rival drugs, yet many express frustration over sustained short interest and the stock's valuation, fueling active speculation around potential acquisition or continued organic growth.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobe is trending amid recent analyst downgrades and concerns over escalating competition, notably from Apple's new creative software suite. The community is sharply divided, with some investors highlighting the company's strong financials and AI integrations as a compelling value opportunity, while others remain bearish, citing potential AI disruption and broader headwinds for the software sector.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

SMCI is trending as a major financial institution recently initiated coverage with a "Sell" rating, citing concerns over shrinking margins in the AI server market despite the company's strong revenue growth and leadership in AI infrastructure. The community is fiercely debating this assessment, with many accusing the institution of manipulation to acquire shares at a discount ahead of anticipated strong earnings, while others remain cautious, pointing to ongoing profitability and governance challenges.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

CleanSpark is trending due to recent analyst upgrades and strong price targets, fueled by its robust Bitcoin mining operations and strategic expansion into AI and high-performance computing datacenters. While bulls anticipate a significant short squeeze and re-rating based on its AI potential, skeptics express frustration over management's execution and the slow realization of AI deals. The company's performance remains closely tied to Bitcoin's price movements, adding another layer of volatility and community debate.

statis crypto Watchlist

Solana

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The timeline extension comes on the heels of the FDA requesting additional information to assess Filspari’s clinical benefit.</li><li>The company submitted responses and the agency determined that the responses constitute a major amendment to the application.&nbsp;</li><li>The FDA is now expected to decide on the application by April 13, 2026.</li></ul>Shares of Travere Therapeutics, Inc., (TVTX) traded 19% lower on Tuesday after the company announced that U.S. Food and Drug Administration (FDA) has extended the review timeline for its application seeking approval of Filspari in focal segmental glomerulosclerosis.The FDA is now <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.travere.com/press-releases/news-details/2026/Travere-Therapeutics-Announces-FDA-Extends-Review-of-sNDA-for-FILSPARI-sparsentan-in-FSGS/default.aspx">expected</a> to decide on the application by April 13, 2026. The agency was initially expected to rule on the application by Jan. 13.<h2 class="st-heading-2">Why The Delay?</h2>The timeline extension comes on the heels of the FDA requesting additional information to assess Filspari’s clinical benefit. The company submitted responses, and the agency determined that the responses constitute a major amendment to the application, and extended the review timeline, the company said. The agency requested no additional information on the safety or manufacturing of Filspari, it added.According to Travere, Filspari would be the first medication indicated for focal segmental glomerulosclerosis if approved. FSGS is a kidney disease causing sclerosis, or scarring in some filters of the kidneys, leading to protein leakage, swelling, and potentially kidney failure.CEO Eric Dube said that the company remains committed to working with the FDA during the extension period and making preparations for a potential commercial launch.Filspari is also approved by the FDA to slow kidney function decline in adults with IgA nephropathy, a chronic autoimmune kidney disease where deposits of the immunoglobulin A (IgA) antibody build up in the kidney's filters, causing inflammation, scarring, and damage.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around TVTX stock jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user opined that the FDA would eventually reject the drug.<stembedurl>https://www.stocktwits.com/Steve_TheBull_Rogers/message/641686497</stembedurl>Another opined that the FDA wouldn’t have extended the review timeline if it was planning on a rejection.<stembedurl>https://www.stocktwits.com/apux/message/641686139</stembedurl><a href="https://stocktwits.com/symbol/TVTX">TVTX stock</a> has gained 48% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/fund-manager-flags-concerns-about-tesla-dwindling-delivery-numbers-high-pe-ratio/cmUXXNkR4Ia">Fund Manager Flags Concerns About Tesla’s Dwindling Delivery Numbers, Notes High P/E Ratio</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Travere Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Travere Therapeutics Stock Slumps After FDA Extends Drug Review Timeline To April: Retail Is Divided On Eventual Approval

According to Travere, Filspari would be the first medication indicated for focal segmental glomerulosclerosis if approved. 

Equity

According to Travere, Filspari would be the first medication indicated for focal segmental glomerulosclerosis if approved. 


<ul class="summary-bullets"><li>Company CEO Doug Ingram said that the company “faced and overcame challenges in 2025.”</li><li>Elevidys, a medicine intended for the treatment of Duchenne muscular dystrophy (DMD), created safety concerns following the death of two patients after treatment.</li><li>Analysts on average expect the company to report total revenue of $2.12 billion for full year 2025.</li></ul> Shares of Sarepta Therapeutics Inc. (SRPT) sank 12% on Monday after the company said that it expects full year 2025 net product revenue of $1.86 billion, marking only slight growth from the $1.79 billion reported for full year 2024.Net product revenue refers to the company’s revenue from its products and does not include collaboration, contract manufacturing or royalty revenue.Analysts on average expect the company to report total revenue of $2.12 billion for full year 2025, according to data from Fiscal AI.<h2 class="st-heading-2">Results Breakdown</h2>Sarepta <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-reports-preliminary-fourth-quarter-and-full-year-2025">now sees</a> revenue from its top-selling gene therapy Elevidys for the full year to come to $898.7 million, including fourth quarter revenue of $110.4 million. The company said that the therapy’s revenue in the three months through the end of December was impacted by the year-end flu season and the need to reschedule six patient infusions into 2026.Revenue from the company’s other therapies for the full year is now expected at $965.6 million.Company CEO Doug Ingram said that the company “faced and overcame challenges in 2025.” “We have important initiatives in 2026 to continue the success of our approved therapies, particularly ELEVIDYS. We previously set a yearly sales floor for ELEVIDYS of $500.0 million. We reconfirm that floor and our intentions to exceed it,” Ingram said on Monday.The company further added that it had $953.8 million in preliminary cash, cash equivalents, restricted cash and investments as of 2025-end. The company will announce its full financial results in late February.<h2 class="st-heading-2">Elevidys Safety Concerns And Other Setbacks</h2>The preliminary numbers come in light of a challenging year for the company. Elevidys, a medicine intended for the treatment of Duchenne muscular dystrophy (DMD), created safety concerns following the death of two patients after treatment. Both non-ambulatory patients suffered from acute liver failure. DMD is a severe, inherited genetic disorder that causes progressive muscle weakness and degeneration.While Sarepta resumed shipments to DMD patients who can walk after a temporary pause, it is now developing a risk-mitigation approach for patients who cannot walk to resume shipments in the particular patient segment.In November, the company also announced that its two approved therapies Amondys 45 and Vyondys 53 in DMD failed in a key confirmatory trial aimed at a traditional full approval for the two. The company, however, continues to eye traditional approval based on the positive risk-benefits of the therapies and real-world evidence.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around SRPT rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours while message volume increased from 'high’ to 'extremely high' levels.A Stocktwits user dismissed the sell-off and opined that the “Elevidys story isn’t broken.” They also noted that the company has enough cash to cover liabilities.<stembedurl>https://www.stocktwits.com/Initiator1/message/641562456</stembedurl>Another dismissed the selloff as a "minor setback."<stembedurl>https://www.stocktwits.com/ZzyzxResearch/message/641561010</stembedurl><a href="https://stocktwits.com/symbol/SRPT">SRPT stock</a> is down 82% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-lvlu-stock-surge-today/cmUaI8XR4Eo">Why Did LVLU Stock More Than Double Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Sarepta Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

SRPT Stock Tumbles 12% On Lackluster Preliminary Revenue Numbers Due To Elevidys Safety Concerns

Sarepta now sees revenue from its top-selling gene therapy Elevidys for the full year to come to $898.7 million.

<ul class="summary-bullets"><li>The company last year in a social media post said that its BlueBird 7 will ship to the Cape Canaveral launch site in October.</li><li>AST said it remains on track to complete 40 phased arrays by early 2026.</li><li>One bullish user predicted the stock price to touch $113 if the current rally breaks the $102 mark.</li></ul>AST SpaceMobile (ASTS) shares soared more than 10% on Friday and were among top trending stocks on Stocktwits as retail investment was buoyed by a recent upgrade from Bank of America.&nbsp;Investors were actively discussing the stock's potential breakout, and the firm's development announcement regarding its BlueBird’s launch in December and the expected fleet to be <a href="https://stocktwits.com/18KGold/message/641353923">launched</a> in 2026, as well as the company's long-term <a href="https://stocktwits.com/StockAnalyst_SA/message/641359044">potential</a> in space communications.&nbsp;Bank of America raised the firm's price target on AST SpaceMobile to $100 from $85 and keeps a ‘Neutral’ rating.BofA in a note said that it is ‘neutral’ on data centers, ‘bullish’ on towers, and projects growing interest in Low-Earth-Orbit (LEO) satellite providers in 2026, as per TheFly.&nbsp;Earlier, Scotiabank had downgraded AST SpaceMobile to ‘Underperform’ from ‘Sector Perform’ with a $45.60 price target.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around ASTS trended in ‘extremely bullish’ territory amid ‘high’ message volumes.&nbsp;One user predicted that Elon Musk may try to buy the firm from the proceeds of SpaceX IPO.&nbsp;<stembedurl>https://stocktwits.com/Longdriver/message/641351687</stembedurl>Another user predicted the stock price to touch $113 if the current rally breaks the $102 mark.&nbsp;<stembedurl>https://stocktwits.com/A1stocks42/message/641349592</stembedurl><h2 class="st-heading-2">Starlink Challenger</h2>BlueBird 6 is AST SpaceMobile’s first next-generation satellite that aims to provide 4G/5G to standard phones and potentially challenge Elon Musk’s Starlink.It was launched last month from India’s Satish Dhawan Space Centre in Sriharikota. The company has said that it is the largest commercial communications array ever deployed in Low-Earth-Orbit.&nbsp;The company last year said in a social media <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/AST_SpaceMobile/status/1973140310478688452">post</a> that its BlueBird 7 will ship to the Cape Canaveral launch site in October. It added that BlueBirds 8-16 are in various stages of production, with launches planned every 1-2 months on average during 2025 and 2026.&nbsp; AST said it remains on track to complete 40 phased arrays by early 2026. It expects 45-60 satellites in orbit by year-end 2026.&nbsp;Shares of AST SpaceMobile have surged nearly 120% in the past six months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

In this photo illustration, the AST SpaceMobile (Space Mobile) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

AST SpaceMobile Has Rallied 120% In Past 6 Months, Retail Still Seeing Upside Potential

Bank of America raised the firm's price target on AST SpaceMobile to $100 from $85 and keeps a ‘Neutral’ rating.

<ul class="summary-bullets"><li>Imcivree is Rhythm’s only approved drug and the company is now looking forward to an FDA approval for the drug in the treatment of acquired hypothalamic obesity.</li><li>The FDA is expected to rule on the company’s application by March 20, 2026.</li><li>The company is also exploring the drug’s potential in treating other rare diseases including congenital hypothalamic obesity and Prader-Willi Syndrome.</li></ul>Shares of Rhythm Pharmaceuticals, Inc. (RYTM) jumped 4% on Friday after the company reported preliminary full-year Imcivree revenue of approximately $194 million, marking a growth of about 50% from FY24.Fourth quarter Imcivree revenue is expected to be about $57 million, marking a quarter-on-quarter growth of 11%. Imcivree is Rhythm’s only approved drug and the company is now looking forward to an approval from the U.S. Food and Drug Administration (FDA) for the drug in the treatment of <a href="https://stocktwits.com/news-articles/markets/equity/rhythm-pharma-experimental-drug-yields-weight-reduction-in-brain-damage-related-obesity/chFy2A1R5KT">acquired hypothalamic obesity.</a>The FDA is expected to rule on the company’s application by March 20, 2026.<h2 class="st-heading-2">Imcivree’s Current Use</h2>Imcivree is currently approved by the FDA to reduce excess body weight and maintain weight reduction long term in adult and pediatric patients two years and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome. Bardet-Biedl syndrome is a rare genetic disorder affecting multiple body systems, characterized by vision loss, obesity, kidney problems, genital abnormalities, and learning disabilities.About 70% of the drug’s revenue for the year and the fourth quarter came from U.S. sales, Rhythm said. The company is also exploring the drug’s potential in treating other rare diseases including congenital hypothalamic obesity and <a href="https://stocktwits.com/news-articles/markets/equity/rhythm-pharmaceuticals-stock-rises-after-positive-study-data-for-setmelanotide-in-treating-genetic-disorder/cLIxj7cREFG">Prader-Willi Syndrome</a> in addition to advancing its other experimental drugs Bivamelagon and RM-718 in acquired hypothalamic obesity.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around RYTM stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.A Stocktwits user opined that the preliminary revenue numbers put speculation of slowing revenue growth to rest.<stembedurl>https://www.stocktwits.com/Stonky_Mcprofitface/message/641320511</stembedurl><a href="https://stocktwits.com/symbol/RYTM">RYTM stock</a> has gained 80% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/general-motors-incurs-7.1-billion-in-charges-in-q4/cmUbl4LR451">General Motors Incurs $7.1B In Charges In Q4 Pertaining To Slowing EV Demand, China Business Restructuring</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Rhythm Pharmaceuticals company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

RYTM Stock Jumps 4% On Imcivree Revenue Growth: Firm Awaits Approval In Acquired Hypothalamic Obesity By March

Fourth quarter Imcivree revenue is expected to be about $57 million, marking a quarter-on-quarter growth of 11%.

<ul class="summary-bullets"><li>KalVista launched Ekterly in the U.S. in July for the treatment of acute attacks of hereditary angioedema in adults and children aged 12 years and older.</li><li>Through the full year 2025, the company recorded global Ekterly revenue of $49 million.</li><li>Kalvista now plans to file a new drug application with the FDA for the drug in pediatric HAE patients aged 2 to 11 years in the third quarter of 2026.</li></ul>Shares of KalVista Pharmaceuticals, Inc. (KALV) jumped 14% after hours on Thursday after the company said that it recorded about $35 million in revenue from its one and only approved drug Ekterly in the fourth quarter, merely months after launch.KalVista <a href="https://stocktwits.com/news-articles/markets/equity/kalvista-gets-fda-approval-for-drug-in-treating-swelling-disorder/chFtmFCR57B">launched</a> Ekterly in the U.S. in July for the treatment of acute attacks of hereditary angioedema in adults and children aged 12 years and older. The company said that in the three months through the end of December, prescription refills surpassed initial prescriptions as the primary driver of revenue.Hereditary angioedema (HAE) is a rare genetic disease caused by deficiency or dysfunction of a protein called the C1 esterase inhibitor, where patients experience painful and debilitating attacks of tissue swelling in various locations of the body that can be life-threatening depending on the area affected.<h2 class="st-heading-2">Ekterly’s Edge</h2>Ekterly is the first and only oral on-demand treatment for HAE, KalVista said, setting it apart from other on-demand HAE treatment options approved in the U.S., which require intravenous or subcutaneous administration.Through the full year 2025, the company recorded global Ekterly revenue of $49 million. The drug is now approved in seven global markets including the U.S., United Kingdom, European Union, Switzerland, Australia, Singapore and Japan.“Fundamental demand has remained strong, with some effects from seasonal variability, and we are encouraged by the continued high level of interest in switching to EKTERLY,” CEO Ben Palleiko said. “Internationally, we are seeing strong uptake in Germany, with early prescribing behaviors mirroring the positive trends we observed in the US, and we expect to expand into other major markets during 2026.”Kalvista now plans to file a new drug application with the FDA for the drug in pediatric HAE patients aged 2 to 11 years in the third quarter of 2026. The company envisions launching the drug for the younger population in the U.S. in 2027.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around KalVista jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.A Stocktwits user applauded the numbers as an “incredible start to Ekterly sales.” “This has a squeeze written all over it,” the user added.<stembedurl>https://www.stocktwits.com/pblegend66/message/641279255</stembedurl>Another user highlighted the drug’s potential and noted that the company could make as much as $340 million in revenue from the drug.<stembedurl>https://www.stocktwits.com/Biocontrol/message/641276040</stembedurl><a href="https://stocktwits.com/symbol/KALV">KALV stock</a> has gained 92% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/general-motors-incurs-7.1-billion-in-charges-in-q4/cmUbl4LR451">General Motors Incurs $7.1B In Charges In Q4 Pertaining To Slowing EV Demand, China Business Restructuring</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

KalVista Pharmaceuticals Stock Rallies After Hours On Strong Genetic Disorder Drug Sales Kickstart

Ekterly is the first and only oral on-demand treatment for HAE, KalVista said, setting it apart from other on-demand HAE treatment options approved in the U.S.

<ul class="summary-bullets"><li>MannKind is now eyeing a potential approval of its Afrezza inhalation powder for children and adolescents living with type 1 or type 2 diabetes.</li><li>H.C. Wainwright reiterated a ‘Buy’ rating on MannKind with an $11 price target after the company’s update.</li><li>The firm said it is positive on MannKind's outlook over the next two years, saying "very little value is ascribed to the multiple tailwinds that could be validated in 2026."</li></ul>MannKind Corporation (MNKD) on Thursday said that it expects two high potential launches going into 2026, driving investor optimism and sending shares up 2%.&nbsp; “With two high-potential launches on the horizon, 2026 is shaping up to be a catalyst-rich year that positions MannKind for long-term value creation,” CEO Michael Castagna<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/01/08/3215359/29517/en/MannKind-Provides-Business-Updates-and-2026-Growth-Drivers.html"> said,</a> while adding that the company closed 2025 “on a high note” with its acquisition of scPharmaceuticals.<h2 class="st-heading-2">MannKind’s Potential Launches</h2>MannKind is now eyeing a potential approval of its Afrezza inhalation powder for children and adolescents living with type 1 or type 2 diabetes. The U.S. Food and Drug Administration is expected to rule on the application by May 29 and if approved, it would be the first needle-free insulin option for pediatric patients in over 100 years of insulin therapy, the company said.The company is also eyeing approval for its FUROSCIX ReadyFlow Autoinjector, developed to deliver a subcutaneous furosemide injection in under 10 seconds as an investigational alternative to the FDA-approved FUROSCIX On-body Infusor. Furosemide is used for treatment of edema in adult patients with chronic heart failure (CHF) or chronic kidney disease (CKD).<h2 class="st-heading-2">Analyst Weighs In</h2>H.C. Wainwright reiterated a ‘Buy’ rating on MannKind with an $11 price target after the company’s update. The price target represents a potential upside of about 88% from the stock's closing price on Wednesday.&nbsp;The firm said it is positive on MannKind's outlook over the next two years, saying "very little value is ascribed to the multiple tailwinds that could be validated in 2026."<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around MNKD shares jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘high’ levels.A Stocktwits user dismissed the company’s Thursday update as “another pump and dump.”<stembedurl>https://www.stocktwits.com/Kool_Aid_Mann/message/641251643</stembedurl><a href="https://stocktwits.com/symbol/MNKD">MNKD stock</a> has dropped 3% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/ford-stock-rallies-on-piper-sandler-upgrade-plans-to-launch-autonomous-driving-on-30000-ev/cmUbiTNR45X">Ford Stock Rallies On Piper Sandler Upgrade, Plans To Launch Autonomous Driving On $30,000 EV</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

MannKind Rallies On Optimism Of Two Imminent Product Launches: Analyst Sees ‘Multiple Headwinds’ For Stock In 2026

The company’s CEO Michael Castagna said that with two high-potential launches on the horizon, 2026 is shaping up to be a catalyst-rich year that positions MannKind for long-term value creation. 

<ul class="summary-bullets"><li>Archer plans to showcase the technology at its recently acquired Hawthorne Municipal Airport facility in Los Angeles.</li><li>IGX Thor is an advanced safety-capable AI computing module.</li><li>Archer said the AI platform will also have applications across manufacturing, fleet operations, and pilot training.</li></ul>Archer Aviation (ACHR) shares rose 5% on Thursday after the company unveiled a major artificial intelligence initiative at the Consumer Electronics Show (CES) 2026, deepening its partnership with NVIDIA to develop next-generation aviation technologies.Archer will integrate NVIDIA’s IGX Thor platform into future versions of its Midnight electric air taxi. IGX Thor is an advanced safety-capable AI computing module, designed for real-time performance.Archer plans to showcase the technology at its recently acquired Hawthorne Municipal Airport facility in Los Angeles, which is expected to serve as the operational hub for its planned LA air taxi network. Archer will also deploy the airport as a testing ground for next-generation aviation technologies.<h2 class="st-heading-2">Partnership Details</h2>The partnership will focus on three areas: enhancing pilot safety through real-time environmental sensing and predictive awareness, enabling smoother integration into complex airspace with AI-driven traffic and routing systems, and building autonomy-ready flight controls that can support future semi-autonomous and autonomous operations. Archer said the AI platform will also have applications across manufacturing, fleet operations, and pilot training.The announcement comes as Archer remains in the spotlight following recent efforts to partner with U.S. cities under the federal eVTOL Integration Pilot Program (eIPP), which aims to support the rollout of air taxis this year. Its applications include public-private partnerships across California, Texas, Florida, Georgia, and New York.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘high’ message volumes. <a href="https://stocktwits.com/symbol/ACHR">ACHR</a> was among the top trending tickers on the platform at the time of writing. &nbsp;<img src="https://news.stocktwits-cdn.com/archr_jpg_294883a2ff.webp" alt="archr.jpg">One user stated that the stock should break and hold above the $9 resistance for further rally.<stembedurl>https://stocktwits.com/fuegie/message/641222039</stembedurl>Over the past year, ACHR shares have declined more than 17%.Read Also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-elvn-stock-shoot-up-60-percent-today/cmUbQNvR45E">ELVN Stock Shot Up 60% Today – What’s Driving The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Midnight electric vertical takeoff and landing (EVTOL) aircraft from the American company Archer Aviation at the 54th International Paris Air Show (SIAE) on June 23, 2023 at Le Bourget. (Photo by Thierry NECTOUX/Gamma-Rapho)

ACHR Stock Gained 5% Today – Why Investors Are Enthusiastic About Its Partnership With NVIDIA? 

Archer will integrate NVIDIA’s IGX Thor platform into future versions of its Midnight electric air taxi.

<ul class="summary-bullets"><li>As of Dec. 22, 2025, 60 heavily pretreated patients were enrolled, and ELVN-001 delivered strong efficacy by 24 weeks.</li><li>Enliven plans to present additional Phase 1 data in mid-2026.</li><li>The company plans to initiate the Phase 3 ENABLE-2 trial in the second half of 2026.</li></ul>Enliven Therapeutics (ELVN) stock surged as high as 60% on Thursday after the company reported positive initial data from its ongoing Phase 1b ENABLE clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia (CML).<a href="https://stocktwits.com/symbol/ELVN">ELVN shares</a> jumped to their highest levels in more than a year on Thursday before paring some of those gains.ELVN-001 is a highly selective small-molecule inhibitor designed to directly target the BCR::ABL gene fusion, the key disease driver in CML. As of Dec. 22, 2025, 60 heavily pretreated patients had been enrolled in the study, with more than half having received four or more prior tyrosine kinase inhibitors (TKIs), including Asciminib and Ponatinib medications. ELVN-001 showed strong efficacy by 24 weeks.In the initial 80 mg once-daily cohort, 38% of patients achieved a major molecular response (MMR), while 16% reached a deep molecular response (DMR). In the randomized 60 mg and 120 mg cohorts, MMR and DMR rates rose to 53% and 35%, respectively. All patients who entered the study already in MMR maintained or improved their responses.The drug demonstrated consistent activity across doses from 60 mg to 120 mg, with no clear dose-response differences observed. Importantly, ELVN-001 was well tolerated, with no maximum tolerated dose identified and no new safety concerns reported.<h2 class="st-heading-2">2026 Pipeline</h2>Enliven plans to present additional Phase 1 data in mid-2026, align with the FDA on dose selection and Phase 3 design, and initiate the Phase 3 ENABLE-2 trial in the second half of 2026.“Momentum has been building over the last year leading to significant interest in our Phase 3 clinical trial from sites all around the world. We are preparing for upcoming regulatory interactions with the FDA to align on dose selection and support initiation of the Phase 3 trial in the second half of 2026,” said Helen Collins, M.D., Chief Medical Officer of Enliven.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘extremely high’ message volumes.<img src="https://news.stocktwits-cdn.com/ELVN_jpg_83e5ce76dc.webp" alt="ELVN.jpg">One user sees $30 as a key resistance point.<stembedurl>https://stocktwits.com/Aburose/message/641205036</stembedurl>The stock has fallen around 1.5% over the past year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-crmd-stock-crash-28-today/cmUbayOR45b">Why Did CRMD Stock Crash 28% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ELVN Stock Shot Up 60% Today – What’s Driving The Rally?

The company reported positive initial data from its ongoing Phase 1b clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia.

<ul class="summary-bullets"><li>The company posted revenue of $126.6 million beating analyst estimates of $81.2 million, according to data from Fiscal.ai.</li><li>Applied Digital has signed leases with two hyperscalers across two campuses in North Dakota with CoreWeave and a U.S. based investment-grade hyperscaler.</li><li>Its adjusted earnings per share came in at breakeven ($0.00). Analysts had expected a loss of $0.12 per share.</li></ul>Applied Digital on Wednesday reported that its second quarter (Q2) revenue more than tripled helped by robust growth in its high-performance computing business.&nbsp;The company posted revenue of $126.6 million, a 250% jump from the prior year comparable period. It also beat analyst estimates of $81.2 million, according to data from Fiscal.ai.“The Dakotas represent a compelling region for hyperscalers due to their cool climate and abundant energy. We believe our first-mover advantage, combined with our proven ability to execute technically complex data center construction, positions Applied Digital with a strong competitive advantage,” said Wes Cummins, Chairman and Chief Executive Officer. &nbsp;&nbsp;The company’s adjusted earnings per share came in at breakeven ($0.00). Analysts had expected a loss of $0.12 per share.&nbsp;Shares in Applied Digital were up nearly 1% in after-market hours of trading.&nbsp;<h2 class="st-heading-2">Strong High-Performance Computing Business</h2>Applied Digital’s HPC hosting business contributed $85 million to the company’s revenue. Its data center hosting contributed $41.6 million, up 15% year-over-year.&nbsp;Applied Digital’s High-Performance Computing (HPC) Hosting Business designs, builds, and operates next-generation data centers, providing massive computing power to support HPC applications in a cost-effective model.It said operations have commenced at its first HPC data center at Polaris Forge 1 with 100 MW of capacity. A second 150 MW HPC data center is under construction at the same campus and is expected to come online in calendar 2026, while a third 150 MW facility is anticipated in calendar 2027.<h2 class="st-heading-2">Lease Agreements</h2>Applied Digital has signed leases with two hyperscalers across two campuses in North Dakota with CoreWeave and a U.S. based investment-grade hyperscaler. These lease agreements bring total leased capacity to 600 MW and aggregate prospective lease revenue to approximately $16 billion before exercise of any renewal options.CoreWeave paid about $85.0 million this quarter, including $73.0 million for tenant fit-out activities and Applied Digital recognized $12.0 million in partial-quarter lease revenue, it said in a statement.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around APLD trended in ‘extremely bullish’ territory amid ‘extremely high’ message volume.&nbsp;Shares in Applied Digital have rallied nearly 200% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of Applied Digital Corporation (NASDAQ: APLD) on July 28, 2025, in Chongqing, China. 

Applied Digital Posts 250% Jump In Its Quarterly Revenue

Applied Digital’s HPC hosting business contributed $85 million. Its data center hosting contributed $41.6 million, up 15% year-over-year. 

<ul class="summary-bullets"><li>Joby first announced its plans to double production in 2027 in December.</li><li>Company CEO JoeBen Bevirt also noted that the new facility can serve as a base for significant future growth.</li><li>The investment comes amid easing in the U.S. regulatory environment pertaining to eVTOLS.</li></ul> Shares of Joby Aviation, Inc. (JOBY) declined over 1% on Wednesday after the eVTOL maker said that it has inked a deal to acquire a manufacturing facility in Dayton, Ohio, for $61.5 million.The new facility spans more than 700,000 feet and is ready for immediate use, the California-based company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.jobyaviation.com/news-events/press-releases/detail/169/joby-to-expand-manufacturing-footprint-with-acquisition-of">said</a>. The deal is part of Joby’s ambitions to double production to four aircrafts per month in 2027.Operations at the new facility, purchased from Capstone STS LLC, are expected to begin this year. Joby already has facilities in California and Ohio and the new facility can serve as a base for “significant future growth,” CEO JoeBen Bevirt noted.<h2 class="st-heading-2">Joby Eyes Manufacturing At Scale</h2>Last year, Joby, which has received millions from Japanese automaker Toyota to support production, completed an expanded manufacturing facility in Marina and started propeller blade production in Ohio. Joby first announced its plans to double production in 2027 in December. The company also said at the time that it has begun procurement of the capital equipment required to double manufacturing capacity.Joby’s investment to expand manufacturing capacity came on the heels of U.S. Secretary of Transportation Sean Duffy unveiling a strategy aimed at improving support for the deployment and integration of electric air taxis. In September, Duffy also announced a new pilot program to allow some aircraft designs to demonstrate eVTOL use cases, such as passenger transportation, cargo delivery, and emergency response, ahead of achieving type certification. The Federal Aviation Administration is expected to deploy the pilot program in 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around JOBY stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<a href="https://stocktwits.com/symbol/JOBY">JOBY stock</a> has gained 57% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-too-good-a-company-to-be-shorted-says-gary-black/cmxyKEtR4cP">Tesla Is ‘Too Good A Company’ To Be Shorted, Says Gary Black: Eyes Multiple ‘Easy’ Fixes At EV Giant</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Joby Aviation, Inc. is displayed on a smartphone screen with a stock market chart in the background, on May 04, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

Joby Inks $61.5 Million Deal To Acquire Another Ready-To-Use Facility In Ohio As It Eyes Doubling eVTOL Production

The new facility spans more than 700,000 feet and is ready for immediate use, the California-based company said.

iShares Trust - iShares ESG Aware 60/40 Balanced Allocation ETF

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

EAOR
iShares ESG Aware 60/40 Balanced Allocation ETF

Feed

News

Sentiment

Fundamentals

Info

Latest EAOR News

EAORiShares ESG Aware 60/40 Balanced Allocation ETF